trans-AUCB
(Synonyms: 反式AUCB,t-AUCB) 目录号 : GC12755
A potent, orally bioavailable sEH inhibitor
Cas No.:885012-33-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: 0.5 nM
trans-AUCB is a potent inhibitor of soluble epoxide hydrolase (sEH).
Soluble epoxide hydrolase (sEH) can convert epoxides to their corresponding diols. Inhibitors of sEH have anti-hypertensive, anti-inflammatory, neuroprotective, and cardioprotective effects.
In vitro: A previous study showed that the pretreatment with DAPT could substantially potentiate the growth inhibition caused by t-AUCB in U251 and U87 cells. Moreover, the pretreatment with DAPT markedly increased t-AUCB-induced apoptosis of U251 and U87 cells. Moreover, T-AUCB alone did not obviously affect caspase-3 activity in the cells, but t-AUCB plus DAPT pretreatment caused significant increase of caspase-3 activity. In addition, the pretreatment with DAPT was able to completely block t-AUCB-induced phosphorylation of p38 MAPK, MAPKAPK2 and Hsp27 in the cells [1].
In vivo: A previous animal study was conducted to investigate the effects of acute sEH inhibition by t-AUCB on infarct volume, functional outcome, and changes in cerebral blood flow (CBF) in a rat model of ischemic stroke. It was found that t-AUCB could significantly reduce cortical infarct volume by 35%, elevate cumulative epoxyeicosatrienoic acids-to-dihydroxyeicosatrienoic acids ratio in brain cortex by twofold, and improve functional outcome in arm-flexion test when compared with that of the vehicle-treated group [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Li JY, Li RJ, Wang HD. γ-secretase inhibitor DAPT sensitizes t-AUCB-induced apoptosis of human glioblastoma cells in vitro via blocking the p38 MAPK/MAPKAPK2/Hsp27 pathway. Acta Pharmacol Sin. 2014 Jun;35(6):825-31.
[2] Shaik JS, Ahmad M, Li W, Rose ME, Foley LM, Hitchens TK, Graham SH, Hwang SH, Hammock BD, Poloyac SM. Soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is neuroprotective in rat model of ischemic stroke. Am J Physiol Heart Circ Physiol. 2013 Dec 1;305(11):H1605-13.
| Cas No. | 885012-33-9 | SDF | |
| 别名 | 反式AUCB,t-AUCB | ||
| 化学名 | 4-[[trans-4-[[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]cyclohexyl]oxy]-benzoic acid | ||
| Canonical SMILES | O=C(O)C(C=C1)=CC=C1O[C@H]2CC[C@H](NC(N[C@@]34CC5C[C@H](C[C@H](C5)C4)C3)=O)CC2 | ||
| 分子式 | C24H32N2O4 | 分子量 | 412.5 |
| 溶解度 | ≤30mg/ml in DMSO;20mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4242 mL | 12.1212 mL | 24.2424 mL |
| 5 mM | 0.4848 mL | 2.4242 mL | 4.8485 mL |
| 10 mM | 0.2424 mL | 1.2121 mL | 2.4242 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。